Literature DB >> 10525729

Bisphosphonates: pharmacology, mechanisms of action and clinical uses.

R G Russell1, P I Croucher, M J Rogers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10525729     DOI： 10.1007/pl00004164

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  48 in total

Review 1.  Conventional treatments for ankylosing spondylitis.

Authors:  M Dougados; B Dijkmans; M Khan; W Maksymowych; Sj van der Linden; J Brandt
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

2.  Binding of nitrogen-containing bisphosphonates (N-BPs) to the Trypanosoma cruzi farnesyl diphosphate synthase homodimer.

Authors:  Chuan-Hsiang Huang; Sandra B Gabelli; Eric Oldfield; L Mario Amzel
Journal:  Proteins       Date:  2010-03

3.  Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws.

Authors:  Meral Günaldi; Cigdem Usul Afsar; Berna Bozkurt Duman; Ismail Oguz Kara; Ufuk Tatli; Berksoy Sahin
Journal:  Oncol Lett       Date:  2015-04-27       Impact factor: 2.967

4.  Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.

Authors:  J A Stakkestad; L I Benevolenskaya; J J Stepan; A Skag; A Nordby; E Oefjord; A Burdeska; I Jonkanski; P Mahoney
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

5.  Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.

Authors:  Diana Olvera; Rachel Stolzenfeld; Joan C Marini; Michelle S Caird; Kenneth M Kozloff
Journal:  J Bone Miner Res       Date:  2018-05-07       Impact factor: 6.741

6.  Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.

Authors:  S Y Tang; M R Allen; R Phipps; D B Burr; D Vashishth
Journal:  Osteoporos Int       Date:  2008-10-11       Impact factor: 4.507

Review 7.  Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Authors:  Beatrice J Edwards; Andrew D Bunta; Joseph Lane; Clarita Odvina; D Sudhaker Rao; Dennis W Raisch; June M McKoy; Imran Omar; Steven M Belknap; Vishvas Garg; Allison J Hahr; Athena T Samaras; Matthew J Fisher; Dennis P West; Craig B Langman; Paula H Stern
Journal:  J Bone Joint Surg Am       Date:  2013-02-20       Impact factor: 5.284

8.  Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up.

Authors:  Philipp Stockmann; Eleftherios Vairaktaris; Falk Wehrhan; Martin Seiss; Stephan Schwarz; Bernd Spriewald; Friedrich-Wilhelm Neukam; Emeka Nkenke
Journal:  Support Care Cancer       Date:  2009-07-17       Impact factor: 3.603

9.  Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.

Authors:  P D Delmas; R R Recker; C H Chesnut; A Skag; J A Stakkestad; R Emkey; J Gilbride; R C Schimmer; C Christiansen
Journal:  Osteoporos Int       Date:  2004-04-08       Impact factor: 4.507

10.  Use of bisphosphonates in prostate cancer: Current status.

Authors:  Rishi Nayyar; Narmada P Gupta
Journal:  Indian J Urol       Date:  2007-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.